Description

Outsourcing is an important means for clinical trial sponsors to bring in outside expertise, from full-service clinical research organisations to smaller functional service providers. The global clinical trial outsourcing market is poised to grow by US$ 17.0 billion from 2022 to 2028, registering a CAGR of 6.1% during the forecast period, according to StrategyHelix.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for clinical trial outsourcing. The global clinical trial outsourcing market is segmented on the basis of phase, application, organization size, and region. By phase, the global clinical trial outsourcing market has been segmented into phase I, phase III, phase III, phase IV. According to the research, the phase III segment had the largest share in the global clinical trial outsourcing market. Based upon application, the global clinical trial outsourcing market is categorized into cardiovascular diseases (CVDs), gastrointestinal diseases, infectious diseases, musculoskeletal disorders (MSD), neurological disorders, oncology, others. In 2021, the oncology segment made up the largest share of revenue generated by the clinical trial outsourcing market. On the basis of organization size, the global clinical trial outsourcing market has been segmented into large enterprises, small and medium-sized enterprises (SMEs). In terms of geography, the global clinical trial outsourcing market has been segmented into North America, Asia Pacific, Europe, Rest of the World (ROW).

The global clinical trial outsourcing market is highly competitive. The key players in the clinical trial outsourcing market include Charles River Laboratories International Inc., ICON plc, IQVIA Holdings Inc., Labcorp Drug Development Inc., Medelis Inc., Parexel International Corporation, Syneos Health Inc., Thermo Fisher Scientific Inc., WuXi AppTec Co. Ltd.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the clinical trial outsourcing market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Phase: phase I, phase III, phase III, phase IV
Application: cardiovascular diseases (CVDs), gastrointestinal diseases, infectious diseases, musculoskeletal disorders (MSD), neurological disorders, oncology, others
Organization size: large enterprises, small and medium-sized enterprises (SMEs)
Region: North America, Asia Pacific, Europe, Rest of the World (ROW)
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

– Get a comprehensive picture of the global clinical trial outsourcing market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Clinical trial outsourcing market overview
Part 3. Market breakdown by phase
– Phase I
– Phase III
– Phase III
– Phase IV
Part 4. Market breakdown by application
– Cardiovascular diseases (CVDs)
– Gastrointestinal diseases
– Infectious diseases
– Musculoskeletal disorders (MSD)
– Neurological disorders
– Oncology
– Others
Part 5. Market breakdown by organization size
– Large enterprises
– Small and medium-sized enterprises (SMEs)
Part 6. Market breakdown by region
– North America
– Asia Pacific
– Europe
– Rest of the World (ROW)
Part 7. Key companies
– Charles River Laboratories International, Inc.
– ICON plc
– IQVIA Holdings, Inc.
– Labcorp Drug Development Inc.
– Medelis, Inc.
– Parexel International Corporation
– Syneos Health, Inc.
– Thermo Fisher Scientific Inc.
– WuXi AppTec Co., Ltd.
About StrategyHelix
Disclaimer